The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Are The Forecasted Market Size Figures For The Prostate Cancer Therapeutics Market In 2026 And 2030?
The prostate cancer therapeutics market size has demonstrated strong growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as a rise in prostate cancer incidence, an aging male population, breakthroughs in oncology drugs, readily available hospital-based cancer care, and increased cancer screening efforts.
The prostate cancer therapeutics market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. The impetus for this growth during the forecast period stems from the uptake of precision oncology, the development of biomarker-driven treatments, an increase in oral oncology drugs, a broadening immunotherapy pipeline, and escalating healthcare expenditure. Noteworthy trends for the forecast period involve the increasing embrace of targeted therapies, the rising deployment of PARP inhibitors, the wider application of immunotherapy in cancer treatment, a transition towards oral cancer medications, and treatment selection guided by precision medicine.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp
What Are The Main Drivers Accelerating The Growth Of The Prostate Cancer Therapeutics Market?
The rising occurrence of prostate cancer is anticipated to boost the expansion of the prostate cancer therapeutics market in the future. Prostate cancer is characterized by the formation of malignant cells in the prostate gland, primarily affecting older males. The growing number of prostate cancer cases is linked to an aging global population, given that the likelihood of developing the condition increases substantially with age, and extended life expectancies mean more men reach an age where they are susceptible. Prostate cancer therapeutics assist in managing this condition by targeting cancerous cells, slowing the disease’s advancement, and enhancing the quality of life through various treatments like surgery, radiation, hormone therapy, and modern approaches such as immunotherapy. As an illustration, Prostate Cancer UK reported in January 2025 that the number of men diagnosed with prostate cancer climbed from 50,751 cases in 2022 to 55,033 cases in 2023. Consequently, the heightened incidence of prostate cancer is fueling the growth of the prostate cancer therapeutics market.
What Segment Types Are Included In The Prostate Cancer Therapeutics Market Analysis?
The prostate cancer therapeutics market covered in this report is segmented –
1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies
2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
5) By End User: Clinics, Hospitals, Other End Users
Subsegments:
1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors
2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens
3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy
5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound
Which Trends Are Affecting The Prostate Cancer Therapeutics Market Framework?
Major companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as an oral once-a-day pill designed for advanced prostate cancer, aiming to enhance patient adherence and overall treatment results. This oral once-a-day medication for advanced prostate cancer describes therapies administered daily to manage metastatic castration-resistant prostate cancer by hindering testosterone’s effects on cancer cells. For example, in January 2024, the India-based company Zydus Lifesciences introduced Rexigo, which is India’s initial oral once-a-day pill containing relugolix for individuals with advanced prostate cancer. This convenient and economical substitute for injectable hormone therapies quickly reduces testosterone, assisting in the control of cancer progression while providing a superior cardiovascular safety profile. Being an oral therapy, it removes the necessity for injectable treatments that require administration by healthcare professionals, thereby offering greater convenience for patients. This introduction signifies a major progression in prostate cancer management within India, equipping patients and doctors with a novel, accessible, secure, and cost-efficient treatment choice.
Which Industry Players Are Present In The Prostate Cancer Therapeutics Market?
Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.
Access The Complete Prostate Cancer Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report
Which Region Is The Dominant Market In The Prostate Cancer Therapeutics Market?
North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Prostate Cancer Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp
Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company
Prostate Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report
Metastatic Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report
Urothelial Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model